Sharfstein Heads FDA Transparency Task Force
Executive Summary
FDA's formation of an internal "Transparency Task Force" is a savvy approach that allows agency leaders to begin making good now on their pledges to enhance openness while giving them six months to decide whether to release any specific new information
You may also be interested in...
Biosimilar Labeling Needs Greater Transparency, BIO And PhRMA Say
Need for informed prescribing demands that products include the data that support biosimilarity, trade groups say in joint petition.
FDA Gets Investor Advice On Transparency At White House Gathering
FDA recently met with venture capitalists and drug industry leaders to discuss the agency's initiative to become more transparent. While such get-togethers are not unusual, the location of this one signaled how significant the topic is to FDA. Rather than meet at the agency's still-being-renovated headquarters in White Oak, participants gathered at the White House
FDA Gets Investor Advice On Transparency At White House Gathering
FDA recently met with venture capitalists and drug industry leaders to discuss the agency's initiative to become more transparent. While such get-togethers are not unusual, the location of this one signaled how significant the topic is to FDA. Rather than meet at the agency's still-being-renovated headquarters in White Oak, participants gathered at the White House